NCT05973110

Brief Summary

Individuals living with a psychotic disorder often experience changes to their thinking and social skills that can lead to challenges with work, school, relationships and living independently. One intervention to target these areas is cognitive remediation therapy, which can be delivered in virtual reality to help apply the skills and strategies learned to day-to-day life. Over the past few years, our team has co-developed a cognitive remediation program in virtual reality with healthcare professionals and people with lived experiences of psychosis. The current trial tests the feasibility and efficacy of this cognitive remediation program in virtual reality at improving thinking skills, social skills, and daily life functioning.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
52

participants targeted

Target at P25-P50 for not_applicable

Timeline
7mo left

Started Jul 2023

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress83%
Jul 2023Dec 2026

First Submitted

Initial submission to the registry

July 4, 2023

Completed
27 days until next milestone

Study Start

First participant enrolled

July 31, 2023

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 2, 2023

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2026

Expected
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2026

Last Updated

April 16, 2026

Status Verified

April 1, 2026

Enrollment Period

2.9 years

First QC Date

July 4, 2023

Last Update Submit

April 13, 2026

Conditions

Keywords

Psychotic DisordersCognitive RemediationVirtual RealityNeurocognitionSocial CognitionCommunity Functioning

Outcome Measures

Primary Outcomes (5)

  • Feasibility of the Intervention (attrition rate).

    The investigators will measure the feasibility of the intervention by verifying adherence and attrition of participants. The percentage of participants who completed the training program will be computed after the participant completes their final intervention visits.

    The training completion will be computed at the 1-week post-intervention timepoint.

  • Feasibility of the intervention (homework completion).

    The investigators will measure the feasibility of the intervention by verifying the homework completion by participants. The percentage of homework completion will be computed after the participant completes their final intervention visit.

    Homework completion will be computed at the 1-week post-intervention timepoint.

  • Feasibility of the intervention (cybersickness).

    The investigators will measure the feasibility of the intervention by creating a composite mean score of cybersickness reported on the Simulator Sickness Questionnaire for each participant. The Simulator Sickness Questionnaire is composed of 16, four-point Likert scale items with responses ranging from "never" to "severe". A higher score on the Simulator Sickness Questionnaire indicates greater cybersickness experienced.

    Participants complete the Simulator Sickness Questionnaire at each intervention visit, which is scheduled twice a week for six weeks. The composite mean score will be computed at the 1-week post-training time point for each participant.

  • Acceptability of the intervention

    The acceptability of the intervention will be measured through a study-specific satisfaction with cognitive remediation intervention questionnaire.

    The satisfaction questionnaire will be administered at the 1-week post-intervention time point.

  • Change in the acceptability of the intervention from the sixth intervention visit (3 weeks in intervention) to 1-week post-intervention.

    The acceptability of the intervention will be measured through the Treatment Acceptability/Adherence Scale (TAAS). Each of the 10 items of The Treatment Acceptability/Adherence Scale is rated on a 7-point Likert-type scale, with responses ranging from 1 ("strongly disagree") to 7 ("strongly agree "). The total score ranges from 10 to 70 with higher score indicating greater acceptability of treatment and greater anticipated ability to adhere to it.

    The Treatment Acceptability/Adherence Scale will be administered at the sixth intervention visit (3 weeks in the intervention) and 1-week post-intervention.

Secondary Outcomes (12)

  • Feasibility of Integrating EMAs into a Clinical Trial

    The completion of the EMA surveys will be computed at the 6-months post-intervention timepoint.

  • Change in the community functioning performance from baseline to 1-week and 3-months post-intervention (Role Functioning Scale).

    Participants complete the Role Functioning Scale at baseline, 1-week post-intervention, and 3-months post-intervention.

  • Change in the community functioning performance from baseline to 1-week and 3-months post-intervention ( modified Global Assessment of Functioning Scale).

    Participants complete the modified Global Assessment of Functioning at baseline, 1-week post-intervention, and 3-months post-intervention

  • Change in the community functioning performance from baseline to 1-week and 3-months post-intervention (UCSD performance-based skills assessment brief).

    Participants complete the measure at baseline, 1-week post-intervention, and 3 months post-intervention.]

  • Change in social cognition performance from baseline to 1-week and 3-months post-intervention (The Hinting Task).

    Participants complete the Hinting Task test at baseline, 1-week post-intervention, and 3 months post-intervention

  • +7 more secondary outcomes

Other Outcomes (11)

  • Symptom Severity at baseline

    Participants complete the Positive and Negative Severity Scale at baseline.

  • Change in Symptom Severity from baseline to 1-week post-intervention and 3-months post-intervention.

    Participants complete the brief version of the Positive and Negative Severity Scale at 1-week post-intervention and 3-months post-intervention.

  • Change in Self-Reported Neurocognition performance from baseline to 1-week, 3-months and 6-months post intervention- Subjective Scale to Investigate Cognition in Schizophrenia - Brief.

    Participants complete the Subjective Scale to Investigate Cognition in Schizophrenia - Brief at baseline, 1-week post-intervention, 3-months post-intervention, and 6-months post-intervention.

  • +8 more other outcomes

Study Arms (2)

Cognitive Remediation

EXPERIMENTAL
Behavioral: Cognitive Remediation

Active Control

ACTIVE COMPARATOR
Behavioral: Active Control

Interventions

In each of the 12 visits, participants will complete exercises in virtual reality for two sessions of about 15 minutes separated by a break of 5 to 10 minutes. Participants then engage in a bridging conversation with study staff for about 15 minutes. More details about each condition will be added after study completion to protect the blinding of our participants.

Cognitive Remediation
Active ControlBEHAVIORAL

In each of the 12 visits, participants will complete exercises in virtual reality will complete exercises in virtual reality for two sessions of about 15 minutes separated by a break of 5 to 10 minutes. Participants then engage in a bridging conversation with study staff for around 10 to 15 minutes. More details about each condition will be added after study completion to protect the blinding of our participants.

Active Control

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Diagnosis of a psychosis-spectrum disorder
  • Equal or between 18 to 60 years old
  • Ability to read and speak English
  • Be clinically stable, as defined as a total Positive And Negative Severity Symptoms score equal or between 30 - 95
  • No changes to their medication dosage, starting a new medication, or stopping a medication within the past month before signing the consent form

You may not qualify if:

  • Neurological or medical disorders that may produce cognitive impairment (including head injury with more than 1 minute of loss of consciousness)
  • Intellectual disability or a score equal or below 70 on the Wechsler Abbreviated Scale of Intelligence.
  • Any vision conditions that cannot be corrected with contact lenses or glasses that can fit in the virtual reality googles.
  • Past history of seizures, fit, and epilepsy
  • Any severe medical condition related to the eyes, ears, and balance
  • History of substance use disorder within the last 3 months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Royal Ottawa Mental Health Centre

Ottawa, Ontario, K1Z 7K4, Canada

RECRUITING

Related Publications (7)

  • Jahn FS, Skovbye M, Obenhausen K, Jespersen AE, Miskowiak KW. Cognitive training with fully immersive virtual reality in patients with neurological and psychiatric disorders: A systematic review of randomized controlled trials. Psychiatry Res. 2021 Jun;300:113928. doi: 10.1016/j.psychres.2021.113928. Epub 2021 Apr 6.

    PMID: 33857847BACKGROUND
  • National Institute of Mental Health (n.d.). Schizophrenia. https://www.nimh.nih.gov/health/topics/schizophrenia

    BACKGROUND
  • Viertio S, Tuulio-Henriksson A, Perala J, Saarni SI, Koskinen S, Sihvonen M, Lonnqvist J, Suvisaari J. Activities of daily living, social functioning and their determinants in persons with psychotic disorder. Eur Psychiatry. 2012 Aug;27(6):409-15. doi: 10.1016/j.eurpsy.2010.12.005. Epub 2011 Mar 5.

    PMID: 21377336BACKGROUND
  • Schroeder AH, Bogie BJM, Rahman TT, Therond A, Matheson H, Guimond S. Feasibility and Efficacy of Virtual Reality Interventions to Improve Psychosocial Functioning in Psychosis: Systematic Review. JMIR Ment Health. 2022 Feb 18;9(2):e28502. doi: 10.2196/28502.

    PMID: 35179501BACKGROUND
  • Shvetz C, Gu F, Drodge J, Torous J, Guimond S. Validation of an ecological momentary assessment to measure processing speed and executive function in schizophrenia. NPJ Schizophr. 2021 Dec 21;7(1):64. doi: 10.1038/s41537-021-00194-9.

    PMID: 34934063BACKGROUND
  • Torous, J., Wisniewski, H., Bird, B., Carpenter, E., David, G., Elejalde, E., Fulford, D., Guimond, S., Hays, R., Henson, P., Hoffman, L., Lim, C., Menon, M., Noel, V., Pearson, J., Peterson, R., Susheela, A., Troy, H., Vaidyam, A., & Weizenbaum, E. (2019). Creating a Digital Health Smartphone App and Digital Phenotyping Platform for Mental Health and Diverse Healthcare Needs: an Interdisciplinary and Collaborative Approach. Journal of Technology in Behavioral Science, 4(2), 73-85. https://doi.org/10.1007/s41347-019-00095-w

    BACKGROUND
  • Yee, J., Matheson, H., Bogie, B. J. M., Thérond, A., Charest, M., van Driel, C., Lei, Y-T., Noël, C., Goyette, M., Cretu, A. M., Tremblay, S., Morris, C., Attwood, D., Baines, A., Stewart, A., Bouchard, S., Bowie, C.R., & Guimond, S. (2023). The development of a user-centered and co-designed virtual reality cognitive remediation program for people living with a psychotic disorder [Manuscript in preparation]. Institute of Mental Health Research, The Royal Ottawa Mental Health Centre.

    BACKGROUND

MeSH Terms

Conditions

Psychotic DisordersSchizophrenia

Interventions

Cognitive Remediation

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic DisordersMental Disorders

Intervention Hierarchy (Ancestors)

Behavior TherapyPsychotherapyBehavioral Disciplines and Activities

Study Officials

  • Synthia Guimond, PhD

    Royal Ottawa Mental Health Centre

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Synthia Guimond, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Masking Details
Due to the nature of the clinical trial, the study staff members delivering the intervention are unable to remain blind and are the only individuals who will be aware of the study arm assignment. Assessment staff members, investigators, and participants will be blinded to study arm assignment and will never be involved in the randomization. The investigator became unblinded mid-way through the project in order to analyze and present some preliminary data. The purpose of this presentation was to secure further funding for the project's continuation.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Participants will be randomized to either 12 sessions over 6 weeks of a cognitive remediation intervention or 12 sessions over 6 weeks of an active control intervention. Both conditions will involve activities in virtual reality.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Scientist

Study Record Dates

First Submitted

July 4, 2023

First Posted

August 2, 2023

Study Start

July 31, 2023

Primary Completion (Estimated)

July 1, 2026

Study Completion (Estimated)

December 1, 2026

Last Updated

April 16, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will share

De-identified data collected from this study may be shared with other researchers at the Royal's Institute of Mental Health Research for analyses and re-analyses. Variables of the study and scripts used for analyses will be made available to the public. De-identified data will also be shared with the general public and researchers upon request. Data that can connect with participants' identity will NOT be used or shared for analyses.

Shared Documents
STUDY PROTOCOL, SAP, ICF, ANALYTIC CODE
Time Frame
De-identified data will become available upon completion of the study and once results have been published in an academic journal (anticipated year of publication: 2026).
Access Criteria
Upon request to Synthia Guimond

Locations